Project Grant R01DK145838
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $614,186 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of intestinal microbiota and immune cell trafficking in acute kidney injury repair. The research examines mechanistic pathways by which immune cells mediate recovery from severe acute kidney injury via microbiome-mediated migration from the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $766,951 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate imaging biomarkers for assessing high-risk deceased donor kidneys slated for transplantation. The project addresses kidney shortage by improving the accuracy of kidney quality assessment, reducing the approximately 2,500 procured kidneys discarded...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $116,625 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct secondary data analysis identifying cardiometabolic subtypes in individuals with prediabetes and linking those subtypes to clinical outcomes. The research employs machine-learning methods to derive and validate novel prediabetes subtypes based on cardiometabolic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Veterans Medical Research Foundation of San Diego $383,098 on September 2, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The recipient will conduct research into kidney tubule dysfunction in APOL1-associated chronic kidney disease, with focus on developing and validating tubular biomarkers that capture kidney functions—nutrient reabsorption and toxin...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Washington $192,763 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), a Project Grant supporting basic and clinical biomedical research that improves understanding of disease mechanisms and leads to improved prevention, diagnosis, and treatment. The award funds a prospective nested cohort study investigating mechanisms of kidney...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $872,273 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify modifiable process delays in deceased donor kidney allocation through process mining analysis. The project applies process mining methodology to discover actual kidney placement workflows from data logs at multiple organ procurement organizations (OPOs). The research...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Alabama at Birmingham $173,232 on May 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds basic research into renal endothelial cell signaling in sepsis-associated acute kidney injury (SA-AKI) preceded by viral priming. The research examines how renal endothelial cells respond to poly(I:C), a synthetic analog of viral double-stranded...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $812,862 on June 12, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify novel biomarkers of early progressive kidney function decline in type 1 diabetes. The research will use urinary and plasma peptidomics—analysis of synthesized peptides and protein degradation fragments—to discover prognostic markers that predict diabetic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Alabama at Birmingham $650,509 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the myeloid ferritin–CXCL3 axis as a driver of acute kidney injury (AKI) progression to chronic kidney disease. The research leverages novel transgenic mice with targeted deletion of ferritin genes in myeloid cells to determine whether myeloid...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $412,992 on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct the Surveillance of Nutritional Risk for Acute Kidney Injury in Critically Ill Kids (SNACK) study. The study evaluates whether poor baseline nutritional status is a modifiable risk factor for acute kidney injury in pediatric intensive care unit patients. The research...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $798,088 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate non-invasive predictive models for assessing acute tubular injury and interstitial fibrosis and tubular atrophy on kidney biopsy. The research leverages the Novel Approaches in the Investigation of Kidney Disease (NAIKID) study, an ongoing prospective cohort at Johns Hopkins that collects blood, urine, kidney tissue, and clinical data from patients undergoing native kidney biopsies. The recipient will analyze data from the first 700 NAIKID participants, measuring blood and urine biomarkers previously associated with adverse kidney outcomes. These biomarkers will be integrated with clinical variables to construct predictive models using kidney biopsy as the gold standard. Subsequent validation will occur across three sites: Johns Hopkins, Mount Sinai, and Yale, leveraging existing kidney biorepositories at the external sites. The work aims to reduce reliance on invasive biopsy procedures and advance precision medicine in kidney disease. Place of performance is Baltimore, Maryland. The period of performance extends through April 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $798.1k | 8/21/26 |